Clinical Trial Update: Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis [Phase 2]

View source ↗

Summary

A Phase 2 trial update on IMUNO BGC Moreau RJ for prophylaxis in high-risk non-muscle invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• IMUNO BGC Moreau RJ

Snippet

Sponsor: Biofabri, S.L | Conditions: Bladder Cancer | Phase 2 | Status: UNKNOWN